Detecting HPV DNA in Anal and Cervical Cancers
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This is a research study for individuals who have cancer associated with human papillomavirus (HPV) and are being treated with radiation as part of standard care for their cancer. Doctors leading this study will use blood tests to find out if they can detect the HPV virus in the blood of study participants before, during, and after radiation treatment. They will also collect blood and archival tumor tissue (from a previous biopsy) to perform other tests in the future that could provide more information about HPV-associated cancers and how they respond to treatment. Participation in this study will last approximately 2 years.
Sponsor: University of Chicago
You may qualify if…
- ✓ Stage I-III anal cancer or stage I-IVA cervical cancer that is p16+ based on immunohistochemistry.
- ✓ Age ≥ 18 years
- ✓ Planned to undergo radiation therapy as definitive treatment, with or without concurrent systemic therapy
You may not qualify if…
- ✕ Anal carcinoma not associated with HPV-16, 18, 31, 33, or 35 will be removed from the
- ✕ Planned to undergo radiation therapy as an adjuvant or post-operative therapy
Where it's recruiting
Chicago
Source: ClinicalTrials.gov · NCT04857528 · last updated 2026-03-04